Back to News
Market Impact: 0.3
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Source: marketbeat.com
Healthcare & BiotechTechnology & InnovationProduct Launches
Editas Medicine is preparing to initiate a first-in-human study of EDIT-401, an in vivo CRISPR-edited therapy intended to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The clinical progression is a positive milestone for Editas's gene-editing pipeline, though efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EDIT0.55
WFC0.05
More News
- Is Berkshire Bending the Rules With Bending Spoons?
- TCW Strategic Income Fund director Haden acquires $267,239 in stock
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong